1-Isopropyl-1-cyclopentanecarboxylic acid | 17206-39-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Isopropyl-1-cyclopentanecarboxylic acid
• 英文别名: 1-isopropylcyclopentane-1-carboxylic acid；1-Isopropyl-cyclopentancarbonsaeure；1-propan-2-ylcyclopentane-1-carboxylic acid
• CAS: 17206-39-2
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: UAFOYVYWSSKWFD-UHFFFAOYSA-N

物化性质

• 沸点：
  146 °C(Press: 30 Torr)
• 密度：
  1.031±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Isopropyl-1-cyclopentanecarboxylic acid 在 双氧水 、 C₆₀H₈₀F₆MnN₆O₆S₂ 作用下， 以 2,2,2-三氟乙醇 、 水 为溶剂， 以9%的产率得到
  参考文献：
  名称：

  非活化一级和二级 γ-C-H 键的高度对映选择性催化内酯化

  摘要：

  手性氧化脂肪族部分在生物和药物相关分子中反复出现，并构成了需要进一步阐述的最通用的功能类型之一。在此，我们报告了一种通过对易获得的羧酸中的强非活化伯键和仲 C( sp 3 )–H 键的对映选择性氧化来直接和一般地获得手性γ -内酯的方案。关键的实现方面是使用强大的空间阻碍锰催化剂，使用过氧化氢作为氧化剂提供出色的对映选择性（高达 >99.9%）和产率（高达 96%）。所得的γ-内酯对于天然产物和可回收聚合物材料的制备具有直接意义。

  DOI：

  10.1021/jacs.3c06231
• 作为产物：
  描述：

  异戊酸乙酯 在 N,N-二甲基丙烯基脲 、 氢氧化钾 、 正丁基锂 、 potassium tert-butylate 、 水 、 二异丙胺 作用下， 反应 6.0h， 生成 1-Isopropyl-1-cyclopentanecarboxylic acid
  参考文献：
  名称：

  New approaches to the synthesis of alkyl-substituted enol lactone systems, inhibitors of the serine protease elastase

  摘要：

  We have synthesized a series of alkyl-substituted enol lactones designed to act as mechanism-based inhibitors of human neutrophil elastase (HLE). General methods were developed for the preparation of alpha- and beta-alkyl-substituted 5-hexynoic acids by the bromoform reaction on the corresponding alkynoic methyl ketone, prepared by an Eschenmoser-Tanabe fragmentation sequence from a suitably substituted cyclohexenone. By this method, beta-methyl- and beta,beta-dimethyl-5-hexynoic acids were synthesized from commercially available isophorone and 3,5-dimethyl-2-cyclohexen-1-one, respectively. Alpha-Substituted 5-hexynoic acids were prepared from 3-ethoxy-2-cyclohexen-1-one, using a novel ZnCl2-mediated alkylation that we developed; this method gives high yields of alpha'-alkylation products, even with secondary halides. The most efficient method for the preparation of alpha-substituted 5-hexynoic acids involved a four-reaction sequence-alkylation of the alpha-substituted ester with 1,4-dibromobutane, elimination, bromination and bisdehydrobromination-that proceeded in high overall yield. Protio enol lactonizations were performed with mercury(II) catalysis in CH2Cl2 or CH2Cl2-H2O. Stereo-selective Z-bromo enol lactonization was carried out by Br+-induced lactonization in the presence of Ag+. E-Bromo enol lactonization with N-bromosuccinimide in CH2Cl2 in the presence of a small amount of water gave better yields and shorter reaction times than the traditional anhydrous conditions. In studies of the inhibitory activity of these lactones toward several proteases (reported in full elsewhere), we found that the alpha-alkyl-substituted protio and bromo enol lactones 1-3 were very good inhibitors of HLE, with k(a)/K(i) values ranging from 14 500 to 37 500 M-1 s-1; the beta-alkyl-substituted enol lactones 5-8 showed only moderate inhibition of HLE.

  DOI：

  10.1021/jo00059a049

文献信息

• [EN] BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS<br/>[FR] COMPOSÉS BENZAMIDES ET IMIDAZOPYRAZINES UTILISÉS COMME INHIBITEURS DE LA BTK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016106623A1

  公开（公告）日：2016-07-07

  Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

  提供的是根据式I的布鲁顿酪氨酸激酶（Btk）抑制剂化合物、其药学上可接受的盐、含有它们的药物组合物或其在治疗中的用途。
• Spiro compounds for treatment of inflammatory disorders
  申请人：Weingarten M. David

  公开号：US20080280974A1

  公开（公告）日：2008-11-13

  Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein Y, Z and R 1 -R 12 are defined herein.

  提供了化合物、药物组合物以及治疗或预防炎症性疾病，特别是哮喘的方法。这些化合物属于一般的I式，或其药用可接受的盐、酯、前药或衍生物：其中Y、Z和R1-R12在此处定义。
• [EN] TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS<br/>[FR] INHIBITEURS DE LA BTK COMPRENANT UNE IMIDAZOPYRAZINE D'ALCOOL TERTIAIRE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016106624A1

  公开（公告）日：2016-07-07

  Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

  根据公式（I），提供了Bruton酪氨酸激酶（Btk）抑制剂化合物，其药用盐，药物组合物或其在治疗中的用途。
• CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP
  申请人：Yamawaki Kenji

  公开号：US20130079319A1

  公开（公告）日：2013-03-28

  A compound of the formula: wherein X is —N═, —CH═, or the like; W is —CH 2 — or the like; U is —S— or the like; R 1 and R 2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; Q is a single bond or the like; R 3 is hydrogen or the like; Ring A is a 6-membered aromatic heterocyclic group having 1-3 nitrogen atoms; each R 4 is independently hydrogen, halogen, or the like; m is an integer from 0 to 2; G is —C(═O)— or the like; D is a single bond, —NH—, or the like; and E is a cyclic quaternary ammonium group, or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.

  该化合物的化学式为：其中X为—N═、—CH═或类似基团；W为—CH2—或类似基团；U为—S—或类似基团；R1和R2各自独立地为氢、卤素、选择性取代的低碳基或类似基团；Q为单键或类似键；R3为氢或类似基团；环A为一个6元芳香杂环基团，具有1-3个氮原子；每个R4独立地为氢、卤素或类似基团；m为0到2的整数；G为—C(═O)—或类似基团；D为单键、—NH—或类似基团；E为一个环状季铵基团，或者是在7侧链上的氨基处的酯、保护化合物、药学上可接受的盐或其溶剂化物。
• LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
  申请人：McCauley John A.

  公开号：US20130296317A1

  公开（公告）日：2013-11-07

  Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO 2 —, —O— or NR ac —, wherein Rac is H, or C 1-20 alkyl and R 1 through R 5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.

  本发明涉及一种公式（I）的化合物及其药学上可接受的盐，其中“A”为S—；—SO—，—SO2—，—O或NRac—，其中Rac为H或C1-20烷基，R1至R5的定义如本文所述。本发明还涉及包含公式I化合物的药物配方以及通过抑制LRRK2激酶活性治疗、管理或改善可治疗、管理或改善的疾病的方法，例如帕金森病。